About / News

July 17, 2008

Cubist Reports First $100 Million Revenue Quarter;
Q2 2008 Total Revenues $101.8 Million;
Total Net Product Revenues $101.4 Million

GAAP Basic and Diluted Net Income of $0.03 Per Share, Reflecting One Time Expenses
Non-GAAP Basic and Diluted Net Income of $0.38 and $0.35 Per Share, Respectively

Earnings Conference Call & Webcast Today (With Slides) at 5:00 p.m. EDT more

July 2, 2008

Cubist to Promote in the U.S. AstraZeneca's Broad Spectrum Antibiotic, MERREM I.V.

- Leverages Proven U.S. Acute Care Sales Organization
- Complements Cubist's Gram-Positive CUBICIN more

July 1, 2008

Cubist to Announce 2Q08 Financial Results on July 17, 2008

more

June 24, 2008

Cubist Testifies on Need to Encourage Antibiotic Research and Development

Antimicrobial Resistance Reaching "Crisis Point" more

June 24, 2008

Cubist Appoints Mark H.N. Corrigan, M.D., to its Board of Directors

more

June 16, 2008

Cubist Appoints Nancy J. Hutson, Ph.D., to its Board of Directors

more

May 30, 2008

Cubist Will Present at the Jefferies & Co. 2nd Annual Healthcare Conference on June 25th, 2008

more

May 1, 2008

Cubist Announces the Adoption of Notice and Access Rule for its 2008 Annual Meeting of Stockholders

2008 Annual Meeting of Stockholders will be Held on Wednesday, June 11th, 2008 at 55 Hayden Avenue, Lexington, MA more

April 24, 2008

Dyax & Cubist Sign Development and Commercialization Agreement for DX-88 Surgical Indications

more

March 24, 2008

Tamara Joseph to Succeed Christopher Guiffre as Cubist's General Counsel

more

March 13, 2008

No Sign of ANDA Filing for Daptomycin

more

March 12, 2008

Cubist Added to S&P SmallCap 600 Index

more

February 12, 2008

Cubist Names Steven C. Gilman, Ph.D., as SVP, Discovery and Non-Clinical and CSO

more

August 17, 2006

NEJM Publishes results of Cubist's Landmark Study of S. aureus Blood Stream Infections

more

May 25, 2006

FDA Approves Expanded Label for IV Antibiotic CUBICIN®

Click here for expanded Label

more